Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) Scholar Rock (NASDAQ: SRRK) resubmitted the apitegromab BLA to the FDA on March 31, 2026, including Catalent Indiana and a second U.S. fill-finish facility. The company expects FDA acceptance within 30 days and a PDUFA action date in late September 2026.Updates were limited in scope, mainly a standard safety update; EMA MAA review is proceeding with a decision anticipated mid-2026. Apitegromab retains Fast Track, Priority Review, Orphan Drug, Rare Pediatric Disease, and EMA PRIME designations.

#SRRK Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

www.stocktitan.net/news/SRRK/scholar-rock-r...

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Scholar Rock (NASDAQ:SRRK) reported Q4 2025 net loss of $91.0M and FY 2025 net loss of $377.9M, with no revenue. The company had $367.6M in cash and marketable securities as of December 31, 2025, and secured a debt facility of up to $550M to support apitegromab commercialization.Apitegromab BLA resubmission is planned after a successful FDA reinspection; FDA and EMA milestones and commercial launch activities are expected through 2026.

#OWL #SRRK Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/OWL/scholar-rock-re...

Earnings to watch Tue, March 3rd, 2026
#AZO #BBY #EVGO #KTB #ONON #PSFE #SE #SRAD #SRRK #TGT #THO #VIK #BOX #CRWD #GTLB #QSI #ROST

Earnings to watch week of March 2, 2026
#AAON #AQN #ASAN #ASTS #AVGO #AZO #BBAI #BBWI #BBY #BILI #BJ #BOX #BULL #BURL #CBRL #CHPT #CIEN #COST #CRDO #CRWD #GAP #GCO #GTLB #GWRE #IOT #INGM #JD #OKTA #ONON #QSI #RDNT #RGTI #RIOT #ROST #SE #SRAD #SRRK #SSYS #SWBI #TGT #THO #TUYA #VEEV #VG #VIK #VSCO

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% | The Motley Fool Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

#SRRK #ee1c6cd3-5651-412f-acea-f8aee72063d5 #coveragefilings

Origin | Interest | Match

Bunny Sero ~ patre0n request 7/? (Link in bio 😋)
#serohanta #srrk

Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026 | The Motley Fool The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.

#SRRK #ad7a8c8d-894e-433e-8a99-cba634c40b28 #coveragefilings #Health #Care

Origin | Interest | Match

Prompt: Library
….

#srrk

Nov 4: library
#fluffvember2025 #srrk

📖

Once upon a time. It’s the way many stories started. Fairy tales, fables, folk tales. Where the down and out became princesses, became knights in shining armour, became rich. They all lived happily ever after. Married, children, loved and cherished. The end.

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BBAI, #RUN, #IONQ, #ALAB, #SRRK

#OptionFlow #OptionsTrading #Trading

#SRRK #6110e7a2-6e01-4052-8f1f-85db7dfdbe95 #investing

Origin | Interest | Match

Scholar Rock Nears FDA Decision: Key Drug Gets Priority Review While Phase 2 Trial Shows Promise FDA sets September decision date for apitegromab as Scholar Rock prepares for commercial launch. Strong $295M cash position funds operations through 2027. See full results.

#SRRK Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

www.stocktitan.net/news/SRRK/scholar-rock-r...

I have an idea for a #srrk and #krbk fic surrounding jealous Sero and jealous Kiri, but have no idea what to put in it except for an interaction between Mina and Sero where she teases him.🥲

// 1.5k wc // CW: #SRRK, NSFW, AFAB terms for Todoroki, AMAB terms for Sero, FWB, top Sero/bottom Todoroki, strap-on, anal sex, masturbation, exhibitionism, Daddy kink, nipple play, titty fucking mention, cum play/cum as lube (kinda?)

Scars
#seroroki #srrk
(ft. trans!Sero)

tw: improper binding methods, self harm

❄️🔥🕸️

When Shoto started liking Hanta, he didn’t know.

market cap over $2B.

#CRCL
#SRRK
#OSCR
#COIN

#SRRK #LLY #NVO #57b17df1-d427-4433-b317-2f65efc9d979 #investing

Origin | Interest | Match

Scholar Rock Secures Fast-Track to Market: FDA Priority Review Sets September Decision for SMA Drug FDA fast-tracks apitegromab review for SMA treatment with September PDUFA date. Strong $364M cash position funds commercial launch plans. See full pipeline updates.

#SRRK Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

www.stocktitan.net/news/SRRK/scholar-rock-r...

White text outlined in red over a black and white spiderweb. Catch A Princess Rating: Explicit Pairing: Sero/Todoroki Kharm's Easter Eggstravaganza 2025 Trans Fem Todoroki Shouto, Spider Sero Hanta, Non-Con to Con By KharmTheRose

Catch A Princess

Kharm's Easter Eggstravaganza 2025

#srrk

archiveofourown.org/works/64835347

commission // #seroroki #srrk #bnha #commission

chibi piece of sero sneaking roki a lil forehead kiss between their classes <3

"rock your world" is up on ao3 <3 if you ever wanted to watch #srrk court each other penguin-style, this is for you! some solid background #bkdk too.

this is the companion to "worth being brave for" so if you liked that, you'll prob like this <3

rts appreciated! link below 💕

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Scholar Rock (NASDAQ: SRRK) announced new Phase 3 SAPPHIRE trial data for apitegromab, their investigational muscle-targeted therapy for Spinal Muscular Atrophy (SMA). The trial met its primary endpoint with statistically significant improvement in motor function, showing a mean difference of 1.8 points (p=0.0192) in Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo.Key secondary endpoints revealed that 30.4% of patients receiving apitegromab achieved ≥3-point HFMSE improvement compared to 12.5% on placebo (p=0.0156). The treatment demonstrated consistent benefits across all subgroups and showed improvements in Revised Upper Limb Module (RULM) and WHO motor development milestones.The drug was well-tolerated with no serious adverse events related to apitegromab, positioning it as a potential complementary therapy to existing SMN-targeted treatments.

#SRRK Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

www.stocktitan.net/news/SRRK/scholar-rock-p...

You guys get a wip bc ily #srrk

Scholar Rock's $437M War Chest: Can Their SMA Drug Deliver Returns for Investors? Scholar Rock submitted BLA for apitegromab in SMA, expects Q4 2025 launch. $437.3M cash extends runway into Q4 2026 with obesity trial data coming Q2 2025.

#SRRK Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

www.stocktitan.net/news/SRRK/scholar-rock-r...